Long-term outcome of nephropathic cystinosis: a 20-year single-center experience
- PMID: 20803298
- DOI: 10.1007/s00467-010-1641-8
Long-term outcome of nephropathic cystinosis: a 20-year single-center experience
Abstract
Nephropathic cystinosis (NC) is a severe disease that is complicated by early-onset chronic renal failure (CRF) and other complications related to cystine deposition in tissue. Since the 1980s, the prognosis of NC has dramatically improved after the introduction of cysteamine treatment. Limited data are available documenting improvement in prognosis. We reviewed our long-term data (follow-up 6.3-27.8 years) on 23 patients followed in the past 26 years. Overall, stage III CRF was reached at 10 years of age in >90% of patients, whereas >80% reached end-stage renal disease before the age of 14 years. Three patients died during the follow-up. Our analysis shows a clear improvement in renal outcome (p = 0.001) and linear growth (p = 0.04) in patients treated more recently. Improvement in the evolution of renal function was significantly associated with early initiation of cysteamine (p = 0.006), with the dose of cysteamine (p = 0.04), and with the use of angiotensin-converting enzyme inhibitors (p = 0.01). Nonrenal long-term complications are similar to previously reported data. Of note, 3/23 patients developed rare forms of primary tumors that were successfully treated. In conclusion, our experience shows a significant improvement in the renal and nonrenal complications of cystinosis over the past decades and highlights the importance of early diagnosis in order to initiate cysteamine as soon as possible.
Similar articles
-
Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults.Kidney Int. 2012 Jan;81(2):179-89. doi: 10.1038/ki.2011.277. Epub 2011 Sep 7. Kidney Int. 2012. PMID: 21900880
-
Cystinosis: renal glomerular and renal tubular function in relation to compliance with cystine-depleting therapy.Pediatr Nephrol. 2015 Jun;30(6):945-51. doi: 10.1007/s00467-014-3018-x. Epub 2014 Dec 20. Pediatr Nephrol. 2015. PMID: 25526929
-
Outcome of infantile nephropathic cystinosis depends on early intervention, not genotype: A multicenter sibling cohort study.J Inherit Metab Dis. 2023 Jan;46(1):43-54. doi: 10.1002/jimd.12562. Epub 2022 Oct 6. J Inherit Metab Dis. 2023. PMID: 36117148
-
Pharmacological treatment of nephropathic cystinosis with cysteamine.Expert Opin Pharmacother. 2004 Nov;5(11):2255-62. doi: 10.1517/14656566.5.11.2255. Expert Opin Pharmacother. 2004. PMID: 15500372 Review.
-
NIH conference. Cystinosis: progress in a prototypic disease.Ann Intern Med. 1988 Oct 1;109(7):557-69. doi: 10.7326/0003-4819-109-7-557. Ann Intern Med. 1988. PMID: 3048161 Review.
Cited by
-
Endocrine complications during and after adolescence in a patient with cystinosis.Ann Pediatr Endocrinol Metab. 2016 Sep;21(3):174-178. doi: 10.6065/apem.2016.21.3.174. Epub 2016 Sep 30. Ann Pediatr Endocrinol Metab. 2016. PMID: 27777912 Free PMC article.
-
Autonomic Nervous System Dysregulation in Monozygous Twins With Nephropathic Cystinosis.Kidney Int Rep. 2018 Jul 29;3(6):1489-1496. doi: 10.1016/j.ekir.2018.07.019. eCollection 2018 Nov. Kidney Int Rep. 2018. PMID: 30450477 Free PMC article. No abstract available.
-
Biomarkers in Nephropathic Cystinosis: Current and Future Perspectives.Cells. 2022 Jun 4;11(11):1839. doi: 10.3390/cells11111839. Cells. 2022. PMID: 35681534 Free PMC article. Review.
-
Potassium regulation in the neonate.Pediatr Nephrol. 2017 Nov;32(11):2037-2049. doi: 10.1007/s00467-017-3635-2. Epub 2017 Apr 4. Pediatr Nephrol. 2017. PMID: 28378030
-
N-acetyl-cysteine is associated to renal function improvement in patients with nephropathic cystinosis.Pediatr Nephrol. 2014 Jun;29(6):1097-102. doi: 10.1007/s00467-013-2705-3. Epub 2013 Dec 11. Pediatr Nephrol. 2014. PMID: 24326786 Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous